Meeting
2023 ASCO Annual Meeting
Phase I/II study of stereotactic radiosurgery with concurrent olaparib followed by adjuvant durvalumab and physician’s choice systemic therapy in patients with breast cancer brain metastases.
Authors
Colette Shen
University of North Carolina at Chapel Hill, Chapel Hill, NC
Colette Shen , Yara Abdou , Linda Chen , Xianming Tan , Gaorav P. Gupta , Filipa Lynce , Mina Lobbous , Erica Michelle Stringer-Reasor , Carey K. Anders
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT04711824
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS1133)
DOI
10.1200/JCO.2023.41.16_suppl.TPS1133
Abstract #
TPS1133
Poster Bd #
343a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
First Author: Zahi Ibrahim Mitri
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
First Author: Neal A. Fischbach
Poster
2020 ASCO Virtual Scientific Program
Phase I/II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of HER2-positive breast cancer brain metastases following stereotactic radiosurgery.
First Author: Alexandra Dos Santos Zimmer